Yoon, Jae-Ho; Kim, Hee-Je; Kwak, Dae-Hun; Park, Sung-Soo; Jeon, Young-Woo; Lee, Sung-Eun; Cho, Byung-Sik; Eom, Ki-Seong; Kim, Yoo-Jin; Lee, Seok; Min, Chang-Ki; Cho, Seok-Goo; Kim, Dong-Wook; Lee, Jong Wook; Min, Woo-Sung
Journal of hematology & oncology
2017Jan ; 10 ( 1 ) :30.
PMID : 28114959
ÀúÀÚ »ó¼¼Á¤º¸
Yoon, Jae-Ho -
Kim, Hee-Je -
Kwak, Dae-Hun -
Park, Sung-Soo -
Jeon, Young-Woo -
Lee, Sung-Eun -
Cho, Byung-Sik -
Eom, Ki-Seong -
Kim, Yoo-Jin -
Lee, Seok -
Min, Chang-Ki -
Cho, Seok-Goo -
Kim, Dong-Wook -
Lee, Jong Wook -
Min, Woo-Sung -
ABSTRACT
Wilms' tumor gene 1 (WT1) expression is a well-known predictor for relapse in acute myeloid leukemia. We monitored WT1 decrement along the treatment course to identify its significant role as a marker for residual disease in acute promyelocytic leukemia (APL) and tried to suggest its significance for relapse prediction. In this single center retrospective study, we serially measured PML-RARa and WT1 expression from 117 APL patients at diagnosis, at post-induction and post-consolidation chemotherapies, and at every 3?months after starting maintenance therapy. All 117 patients were in molecular remission after treatment of at least 2 consolidation chemotherapies. We used WT1 ProfileQuant??kit (Ipsogen) for WT1 monitoring. High WT1 expression (>120 copies/10(4) ABL1) after consolidation and at early period (3?months) after maintenance therapy significantly predicted subsequent relapse. All paired PML-RARa RQ-PCR were not detected except for one sample with early relapse. Patients with high WT1 expression at 3?months after maintenance therapy (n?=?40) showed a significantly higher relapse rate (30.5 vs. 6.9%, P?
Acute promyelocytic leukemia, WT1, FLT3 mutation, Minimal residual disease
¸µÅ©